Thought Leadership

Latest Report

The US Payer Problem

The pharma world is on tenterhooks, waiting to see how the Inflation Reduction Act will impact drug innovation and pricing, and how the Federal Trade Commission could foil M&A plans. As valid as these concerns are, however, they shouldn't overshadow what is arguably a more pressing issue: the shifting dynamics in the US payer landscape. The…

Report library

Thumbnail

PD(L)anner - December 2021

In this special report, we provide you with the latest Evaluate Vantage update on clinical and regulatory developments in the PD-(L)1 inhibitor space. Among other issues,…

Thumbnail

ASH 2021 Conference Round Up

This article pack, produced by Evaluate Vantage’s team of award-winning journalists, presents expert analysis and insights on data recently presented at the 63rd annual…

Thumbnail

Infographic: Evaluate Vantage 2022 Preview

Leading up to the publication of the Evaluate Vantage 2022 Preview, we created this Infographic to provide a snapshot of the products and companies that are driving top…

Thumbnail

Evaluate Vantage 2022 Preview Report

Covid-19 will still be a front-page story in 2022, keeping the biopharma sector in the spotlight. The attention will bring some benefits, largely in the shape of broad…

Thumbnail

Biopharma Quarterly Round Up (Q3 2021)

This article pack, produced by the editorial team at Evaluate Vantage, explores the key developments and decisions that are impacting the biopharma landscape. Access…

Thumbnail

Covid Round Up (2021)

The biopharma and medtech sectors have been racing to deliver treatments, vaccines and other solutions to Covid-19 for close to two years now. What progress has been made…

Thumbnail

2021 IASLC World Conference on Lung Cancer

The year-end oncology congress season kicked off with the annual IASLC World Conference on Lung Cancer. While it took place in virtual format from September 8-14, this…